

Silvana Galderisi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3157976/publications.pdf>

Version: 2024-02-01

230
papers

12,738
citations

28274

55
h-index

29157

104
g-index

256
all docs

256
docs citations

256
times ranked

12027
citing authors

#	ARTICLE	IF	CITATIONS
1	How mental health care should change as a consequence of the COVID-19 pandemic. <i>Lancet Psychiatry</i> , 2020, 7, 813-824.	7.4	1,101
2	Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. <i>Lancet</i> , 2008, 371, 1085-1097.	13.7	964
3	Toward a new definition of mental health. <i>World Psychiatry</i> , 2015, 14, 231-233.	10.4	383
4	The current conceptualization of negative symptoms in schizophrenia. <i>World Psychiatry</i> , 2017, 16, 14-24.	10.4	354
5	The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. <i>World Psychiatry</i> , 2014, 13, 275-287.	10.4	346
6	EEG microstate duration and syntax in acute, medication-naïve, first-episode schizophrenia: a multi-center study. <i>Psychiatry Research - Neuroimaging</i> , 2005, 138, 141-156.	1.8	316
7	Negative symptoms of schizophrenia: new developments and unanswered research questions. <i>Lancet Psychiatry</i> , 2018, 5, 664-677.	7.4	316
8	Prevention of Psychosis. <i>JAMA Psychiatry</i> , 2020, 77, 755.	11.0	287
9	Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST). <i>American Journal of Psychiatry</i> , 2009, 166, 675-682.	7.2	284
10	The status of spectral EEG abnormality as a diagnostic test for schizophrenia. <i>Schizophrenia Research</i> , 2008, 99, 225-237.	2.0	255
11	Sources of cortical rhythms in adults during physiological aging: A multicentric EEG study. <i>Human Brain Mapping</i> , 2006, 27, 162-172.	3.6	253
12	Deconstructing Vulnerability for Psychosis: Meta-Analysis of Environmental Risk Factors for Psychosis in Subjects at Ultra High-Risk. <i>European Psychiatry</i> , 2017, 40, 65-75.	0.2	241
13	Oxytocin receptor polymorphisms and adult attachment style in patients with depression. <i>Psychoneuroendocrinology</i> , 2009, 34, 1506-1514.	2.7	221
14	Interplay Among Psychopathologic Variables, Personal Resources, Context-Related Factors, and Real-life Functioning in Individuals With Schizophrenia. <i>JAMA Psychiatry</i> , 2018, 75, 396.	11.0	214
15	The cortical generators of P3a and P3b: A LORETA study. <i>Brain Research Bulletin</i> , 2007, 73, 220-230.	3.0	210
16	Evaluation of two new neuropsychological tests designed to minimize cultural bias in the assessment of HIV-1 seropositive persons: A WHO study. <i>Archives of Clinical Neuropsychology</i> , 1993, 8, 123-135.	0.5	201
17	Deficit schizophrenia: an update. <i>World Psychiatry</i> , 2008, 7, 143-147.	10.4	171
18	United Nations convention on the rights of persons with disabilities needs to be interpreted on the basis of scientific evidence regarding psychiatry. <i>European Psychiatry</i> , 2018, 51, 87-89.	0.2	166

#	ARTICLE	IF	CITATIONS
19	Schizophrenia--Time to Commit to Policy Change. <i>Schizophrenia Bulletin</i> , 2014, 40, S165-S194.	4.3	153
20	The clinical characterization of the patient with primary psychosis aimed at personalization of management. <i>World Psychiatry</i> , 2021, 20, 4-33.	10.4	153
21	Categorical and dimensional approaches to negative symptoms of schizophrenia: Focus on long-term stability and functional outcome. <i>Schizophrenia Research</i> , 2013, 147, 157-162.	2.0	148
22	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMISE): a three-phase switching study. <i>Lancet Psychiatry</i> , 2018, 5, 797-807.	7.4	141
23	Persistent negative symptoms in first episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial. <i>European Neuropsychopharmacology</i> , 2013, 23, 196-204.	0.7	137
24	Historical, Psychopathological, Neurological, and Neuropsychological Aspects of Deficit Schizophrenia: A Multicenter Study. <i>American Journal of Psychiatry</i> , 2002, 159, 983-990.	7.2	127
25	The Brief Negative Symptom Scale (BNSS): Independent validation in a large sample of Italian patients with schizophrenia. <i>European Psychiatry</i> , 2015, 30, 641-647.	0.2	114
26	Primary and persistent negative symptoms: Concepts, assessments and neurobiological bases. <i>Schizophrenia Research</i> , 2017, 186, 19-28.	2.0	110
27	Is avolition in schizophrenia associated with a deficit of dorsal caudate activity? A functional magnetic resonance imaging study during reward anticipation and feedback. <i>Psychological Medicine</i> , 2015, 45, 1765-1778.	4.5	108
28	Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: An open randomized clinical trial (EUFEST). <i>Schizophrenia Research</i> , 2009, 115, 97-103.	2.0	107
29	Correlates of cognitive impairment in first episode schizophrenia: The EUFEST study. <i>Schizophrenia Research</i> , 2009, 115, 104-114.	2.0	102
30	Cross-cultural Validation of the 5-Factor Structure of Negative Symptoms in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2019, 45, 305-314.	4.3	99
31	The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients. <i>World Psychiatry</i> , 2020, 19, 81-91.	10.4	96
32	Magnetic Resonance Imaging and the Prediction of Outcome in First-Episode Schizophrenia: A Review of Current Evidence and Directions for Future Research. <i>Schizophrenia Bulletin</i> , 2015, 41, 574-583.	4.3	94
33	EPA guidance on assessment of negative symptoms in schizophrenia. <i>European Psychiatry</i> , 2021, 64, e23.	0.2	94
34	Inhibition of auditory cortical responses to ipsilateral stimuli during dichotic listening: evidence from magnetoencephalography. <i>European Journal of Neuroscience</i> , 2004, 19, 2329-2336.	2.6	90
35	Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on Psychoses. <i>JAMA Psychiatry</i> , 2021, 78, 550.	11.0	89
36	Network Analysis Reveals the Latent Structure of Negative Symptoms in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2019, 45, 1033-1041.	4.3	88

#	ARTICLE	IF	CITATIONS
37	Patterns of Structural MRI Abnormalities in Deficit and Nondeficit Schizophrenia. <i>Schizophrenia Bulletin</i> , 2007, 34, 393-401.	4.3	85
38	Evidence-Based Medicine and Electrophysiology in Schizophrenia. <i>Clinical EEG and Neuroscience</i> , 2009, 40, 62-77.	1.7	85
39	Primary, Enduring Negative Symptoms: An Update on Research. <i>Schizophrenia Bulletin</i> , 2017, 43, 730-736.	4.3	85
40	Deficit schizophrenia: An overview of clinical, biological and treatment aspects. <i>European Psychiatry</i> , 2009, 24, 493-500.	0.2	84
41	Neurobiological background of negative symptoms. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 543-558.	3.2	81
42	Evaluation of two new neuropsychological tests designed to minimize cultural bias in the assessment of HIV-1 seropositive persons: a WHO study. <i>Archives of Clinical Neuropsychology</i> , 1993, 8, 123-35.	0.5	79
43	Ventricle-to-brain ratio in schizophrenia: a controlled follow-up study. <i>Biological Psychiatry</i> , 1989, 26, 756-759.	1.3	78
44	Neuropsychological Slowness in Obsessive-Compulsive Patients. <i>British Journal of Psychiatry</i> , 1995, 167, 394-398.	2.8	78
45	Brain Hemispheric Organization, Anxiety, and Psychoses. <i>CNS Spectrums</i> , 2000, 5, 58-69.	1.2	76
46	The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors. <i>European Psychiatry</i> , 2019, 58, 1-9.	0.2	75
47	Frequency and clinical correlates of adult separation anxiety in a sample of 508 outpatients with mood and anxiety disorders. <i>Acta Psychiatrica Scandinavica</i> , 2010, 122, 40-46.	4.5	73
48	Evaluation of two new neuropsychological tests designed to minimize cultural bias in the assessment of HIV-1 seropositive persons: A WHO study. <i>Archives of Clinical Neuropsychology</i> , 1993, 8, 123-135.	0.5	72
49	EPA guidance on treatment of negative symptoms in schizophrenia. <i>European Psychiatry</i> , 2021, 64, e21.	0.2	70
50	Alexithymia and Cognitive Dysfunctions in Patients with Panic Disorder. <i>Psychotherapy and Psychosomatics</i> , 2008, 77, 182-188.	8.8	66
51	Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives. <i>Schizophrenia Research</i> , 2016, 175, 154-160.	2.0	66
52	Social cognition in people with schizophrenia: a cluster-analytic approach. <i>Psychological Medicine</i> , 2016, 46, 2717-2729.	4.5	65
53	The Specific Level of Functioning Scale: Construct validity, internal consistency and factor structure in a large Italian sample of people with schizophrenia living in the community. <i>Schizophrenia Research</i> , 2014, 159, 144-150.	2.0	64
54	The "Insight Paradox" in Schizophrenia: Magnitude, Moderators and Mediators of the Association Between Insight and Depression. <i>Schizophrenia Bulletin</i> , 2016, 42, 1225-1233.	4.3	61

#	ARTICLE	IF	CITATIONS
55	Executive hypercontrol in obsessive-compulsive disorder: electrophysiological and neuropsychological indices. <i>Clinical Neurophysiology</i> , 2004, 115, 1340-1348.	1.5	60
56	A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. <i>European Neuropsychopharmacology</i> , 2019, 29, 947-959.	0.7	60
57	Pharmac-EEG in Psychiatry. <i>Clinical EEG and Neuroscience</i> , 2006, 37, 81-98.	1.7	59
58	Clinical, biological, and neuropsychological features associated with lateral ventricular enlargement in DSM-III schizophrenic disorder. <i>Psychiatry Research</i> , 1987, 21, 137-149.	3.3	58
59	Induced Gamma Activity and Event-Related Coherence in Schizophrenia. <i>Clinical EEG and Neuroscience</i> , 2007, 38, 96-104.	1.7	57
60	Double dissociation of N1 and P3 abnormalities in deficit and nondeficit schizophrenia. <i>Schizophrenia Research</i> , 2007, 92, 252-261.	2.0	57
61	CEEG mapping in drug-free schizophrenics. <i>Schizophrenia Research</i> , 1991, 6, 15-23.	2.0	56
62	Ala147Thr substitution in translocator protein is associated with adult separation anxiety in patients with depression. <i>Psychiatric Genetics</i> , 2009, 19, 110-111.	1.1	56
63	Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies—PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice. <i>Schizophrenia Bulletin</i> , 2020, 46, 432-441.	4.3	56
64	No gender differences in social outcome in patients suffering from schizophrenia. <i>European Psychiatry</i> , 2012, 27, 406-408.	0.2	53
65	Disorganization and real-world functioning in schizophrenia: Results from the multicenter study of the Italian Network for Research on Psychoses. <i>Schizophrenia Research</i> , 2018, 201, 105-112.	2.0	52
66	Clinical and neuropsychological correlates of cerebral ventricular enlargement in schizophrenia. <i>Journal of Psychiatric Research</i> , 1985, 19, 587-596.	3.1	51
67	Catechol-O-Methyltransferase Val ¹⁵⁸ Met Polymorphism in Schizophrenia: Associations with Cognitive and Motor Impairment. <i>Neuropsychobiology</i> , 2005, 52, 83-89.	1.9	51
68	QEEG alpha1 changes after a single dose of high-potency neuroleptics as a predictor of short-term response to treatment in schizophrenic patients. <i>Biological Psychiatry</i> , 1994, 35, 367-374.	1.3	50
69	Neurocognitive functioning in subjects with eating disorders: the influence of neuroactive steroids. <i>Biological Psychiatry</i> , 2003, 53, 921-927.	1.3	50
70	Transcranial direct current stimulation for hyperactivity and noncompliance in autistic disorder. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 361-366.	2.6	50
71	Stereotaxy-Based Regional Brain Volumetry Applied to Segmented MRI: Validation and Results in Deficit and Nondeficit Schizophrenia. <i>NeuroImage</i> , 2002, 17, 373-384.	4.2	49
72	Personal resources and depression in schizophrenia: The role of self-esteem, resilience and internalized stigma. <i>Psychiatry Research</i> , 2017, 256, 359-364.	3.3	49

#	ARTICLE	IF	CITATIONS
73	Modified nutritional counselling to increase motivation to treatment in anorexia nervosa. <i>European Psychiatry</i> , 2005, 20, 186-187.	0.2	48
74	Comorbid substance abuse in first-episode schizophrenia: Effects on cognition and psychopathology in the EUFEST study. <i>Schizophrenia Research</i> , 2013, 147, 132-139.	2.0	48
75	Social skills and neurocognitive individualized training in schizophrenia: comparison with structured leisure activities. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010, 260, 305-315.	3.2	47
76	Reward anticipation and trait anhedonia: An electrophysiological investigation in subjects with schizophrenia. <i>Clinical Neurophysiology</i> , 2016, 127, 2149-2160.	1.5	45
77	The complex relationship between self-reported "personal recovery" and clinical recovery in schizophrenia. <i>Schizophrenia Research</i> , 2018, 192, 108-112.	2.0	45
78	Premorbid academic and social functioning in patients with schizophrenia and its associations with negative symptoms and cognition. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 253-266.	4.5	44
79	COMT Val158Met and BDNF C270T polymorphisms in schizophrenia: a case-control study. <i>Schizophrenia Research</i> , 2005, 73, 27-30.	2.0	42
80	Neurophysiological correlates of Avolition-apathy in schizophrenia: A resting-EEG microstates study. <i>NeuroImage: Clinical</i> , 2018, 20, 627-636.	2.7	39
81	Hemispheric asymmetry and psychopathological dimensions in drug-free patients with schizophrenia. <i>International Journal of Psychophysiology</i> , 1999, 34, 293-301.	1.0	38
82	European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP). <i>European Neuropsychopharmacology</i> , 2019, 29, 1301-1311.	0.7	38
83	Familial aggregation of MATRICS Consensus Cognitive Battery scores in a large sample of outpatients with schizophrenia and their unaffected relatives. <i>Psychological Medicine</i> , 2018, 48, 1359-1366.	4.5	37
84	Computerized EEG topography findings in schizophrenic patients before and after haloperidol treatment. <i>International Journal of Psychophysiology</i> , 1992, 13, 283-290.	1.0	35
85	Gender Differences in Clinical and Psychosocial Features Among Persons With Schizophrenia: A Mini Review. <i>Frontiers in Psychiatry</i> , 2021, 12, 789179.	2.6	35
86	Neurocognitive indices of executive hypercontrol in obsessive-compulsive disorder. <i>Acta Psychiatrica Scandinavica</i> , 2007, 115, 380-387.	4.5	34
87	The relationships of personal resources with symptom severity and psychosocial functioning in persons with schizophrenia: results from the Italian Network for Research on Psychoses study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 285-294.	3.2	33
88	Electrophysiological Aberrations Associated with Negative Symptoms in Schizophrenia. <i>Current Topics in Behavioral Neurosciences</i> , 2014, 21, 129-156.	1.7	32
89	Functional connectivity of the ventral tegmental area and avolition in subjects with schizophrenia: a resting state functional MRI study. <i>European Neuropsychopharmacology</i> , 2018, 28, 589-602.	0.7	32
90	Relationship between CSF noradrenaline levels, EEG indicators of activation and psychosis ratings in drug-free schizophrenic patients. <i>Acta Psychiatrica Scandinavica</i> , 1985, 71, 19-24.	4.5	31

#	ARTICLE	IF	CITATIONS
91	Transcranial Direct Current Stimulation for Autistic Disorder. <i>Biological Psychiatry</i> , 2014, 76, e5-e6.	1.3	31
92	Dissecting negative symptoms of schizophrenia: History, assessment, pathophysiological mechanisms and treatment. <i>Schizophrenia Research</i> , 2017, 186, 1-2.	2.0	31
93	Avolition-Apathy and White Matter Connectivity in Schizophrenia: Reduced Fractional Anisotropy Between Amygdala and Insular Cortex. <i>Clinical EEG and Neuroscience</i> , 2018, 49, 55-65.	1.7	31
94	Dorsolateral prefrontal cortex volume in patients with deficit or nondeficit schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 37, 264-269.	4.8	30
95	Shall we really say goodbye to first rank symptoms?. <i>European Psychiatry</i> , 2016, 37, 8-13.	0.2	30
96	Categorizing and assessing negative symptoms. <i>Current Opinion in Psychiatry</i> , 2017, 30, 201-208.	6.3	30
97	The association between insight and depressive symptoms in schizophrenia: Undirected and Bayesian network analyses. <i>European Psychiatry</i> , 2020, 63, 1-21.	0.2	30
98	Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning. <i>European Neuropsychopharmacology</i> , 2020, 34, 76-86.	0.7	30
99	A proposed new definition of mental health. <i>Psychiatria Polska</i> , 2017, 51, 407-411.	0.5	29
100	Value of schizophrenia treatment I: The patient journey. <i>European Psychiatry</i> , 2018, 53, 107-115.	0.2	28
101	A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 238-251.	2.1	28
102	Conditional Associative Learning in Drug-Free Schizophrenic Patients. <i>Neuropsychobiology</i> , 1987, 17, 30-34.	1.9	27
103	Neurocognitive functioning in bulimia nervosa: the role of neuroendocrine, personality and clinical aspects. <i>Psychological Medicine</i> , 2011, 41, 839-848.	4.5	26
104	Unmet needs in patients with first-episode schizophrenia: a longitudinal perspective. <i>Psychological Medicine</i> , 2012, 42, 1461-1473.	4.5	26
105	Investigation of endocannabinoid system genes suggests association between peroxisome proliferator activator receptor-1 α gene (PPARA) and schizophrenia. <i>European Neuropsychopharmacology</i> , 2013, 23, 749-759.	0.7	26
106	Characterization of premorbid functioning during childhood in patients with deficit vs. non-deficit schizophrenia and in their healthy siblings. <i>Schizophrenia Research</i> , 2016, 174, 172-176.	2.0	25
107	Multilead quantitative EEG profile of clozapine in resting and vigilance-controlled conditions. <i>Psychiatry Research - Neuroimaging</i> , 1996, 67, 113-122.	1.8	24
108	NRG1 and BDNF genes in schizophrenia: An association study in an Italian case-control sample. <i>Psychiatry Research</i> , 2010, 176, 82-84.	3.3	24

#	ARTICLE	IF	CITATIONS
109	Neurocognitive individualized training versus social skills individualized training: A randomized trial in patients with schizophrenia. <i>Schizophrenia Research</i> , 2013, 150, 69-75.	2.0	24
110	Cerebral connectivity and psychotic personality traits. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 292-299.	3.2	23
111	Disorganization and cognitive impairment in schizophrenia: New insights from electrophysiological findings. <i>International Journal of Psychophysiology</i> , 2019, 145, 99-108.	1.0	23
112	Primary prevention of depression: An umbrella review of controlled interventions. <i>Journal of Affective Disorders</i> , 2021, 294, 957-970.	4.1	23
113	The reliability and clinical utility of ICD-11 schizoaffective disorder: A field trial. <i>Schizophrenia Research</i> , 2019, 208, 235-241.	2.0	22
114	Decrease of functional coupling between left and right auditory cortices during dichotic listening: An electroencephalography study. <i>Neuroscience</i> , 2005, 136, 323-332.	2.3	21
115	Pharmac-EEG: A History of Progress and a Missed Opportunity. <i>Clinical EEG and Neuroscience</i> , 2006, 37, 61-65.	1.7	21
116	The influence of autistic symptoms on social and non-social cognition and on real-life functioning in people with schizophrenia: Evidence from the Italian Network for Research on Psychoses multicenter study. <i>European Psychiatry</i> , 2020, 63, e98.	0.2	20
117	Transitions in mental health care: The European Psychiatric Association contribution to reform in Bulgaria. <i>European Psychiatry</i> , 2020, 63, 1-13.	0.2	20
118	A systematic review on shared biological mechanisms of depression and anxiety in comorbidity with psoriasis, atopic dermatitis, and hidradenitis suppurativa. <i>European Psychiatry</i> , 2021, 64, e71.	0.2	20
119	Lateralization patterns of verbal stimuli processing assessed by reaction time and event-related potentials in schizophrenic patients. <i>International Journal of Psychophysiology</i> , 1988, 6, 167-176.	1.0	19
120	Qualitative MRI findings in patients with schizophrenia: a controlled study. <i>Psychiatry Research - Neuroimaging</i> , 2000, 98, 117-126.	1.8	19
121	Factors associated with increased noradrenaline levels in schizophrenic patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1990, 14, 49-59.	4.8	18
122	Accuracy of self-assessment of real-life functioning in schizophrenia. <i>NPJ Schizophrenia</i> , 2021, 7, 11.	3.6	18
123	Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the "real-life". <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 109, 110250.	4.8	18
124	Negative Symptoms of Schizophrenia and Dopaminergic Transmission: Translational Models and Perspectives Opened by iPSC Techniques. <i>Frontiers in Neuroscience</i> , 2020, 14, 632.	2.8	17
125	"Simple schizophrenia": a controlled MRI and clinical/neuropsychological study. <i>Psychiatry Research - Neuroimaging</i> , 1999, 91, 175-184.	1.8	16
126	Hemispheric lateralization patterns and psychotic experiences in healthy subjects. <i>Psychiatry Research - Neuroimaging</i> , 2005, 139, 141-154.	1.8	16

#	ARTICLE	IF	CITATIONS
127	Acute Effects of Music Therapy in Subjects With Psychosis During Inpatient Treatment. <i>Psychiatry (New York)</i> , 2018, 81, 218-227.	0.7	16
128	C-EEG brain mapping in DSM-III schizophrenics after acute and chronic haloperidol treatment. <i>European Neuropsychopharmacology</i> , 1990, 1, 51-54.	0.7	15
129	Brain electrical microstates in subjects with panic disorder. <i>Brain Research Bulletin</i> , 2001, 54, 427-435.	3.0	15
130	Attitudes of patients with schizophrenia and depression to psychiatric research: a study in seven European countries. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2011, 46, 159-165.	3.1	15
131	The interrelation of needs and quality of life in first-episode schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 207-216.	3.2	15
132	Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. <i>European Psychiatry</i> , 2021, 64, e7.	0.2	15
133	Improving Knowledge on Pathways to Functional Outcome in Schizophrenia: Main Results From the Italian Network for Research on Psychoses. <i>Frontiers in Psychiatry</i> , 2021, 12, 791117.	2.6	15
134	Updated perspectives on the clinical significance of negative symptoms in patients with schizophrenia. <i>Expert Review of Neurotherapeutics</i> , 2022, 22, 541-555.	2.8	15
135	Lateralization patterns of event-related potential and performance indices in schizophrenia: relationship to clinical state and neuroleptic treatment. <i>International Journal of Psychophysiology</i> , 1991, 10, 225-230.	1.0	13
136	Emotions, Brain Development, and Psychopathologic Vulnerability. <i>CNS Spectrums</i> , 2000, 5, 44-48.	1.2	13
137	Physiological Correlates of Positive Symptoms in Schizophrenia. <i>Current Topics in Behavioral Neurosciences</i> , 2014, 21, 103-128.	1.7	13
138	European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study. <i>Frontiers in Psychiatry</i> , 2022, 13, 826465.	2.6	13
139	Cognitive-enhancing effects of aripiprazole: a case report. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2008, 4, 24.	1.2	12
140	SoCIAL – training cognition in schizophrenia: a pilot study. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 1947-1956.	2.2	12
141	Assessment of de novo copy-number variations in Italian patients with schizophrenia: Detection of putative mutations involving regulatory enhancer elements. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 126-136.	2.6	12
142	Can IQ moderate the response to cognitive remediation in people with schizophrenia?. <i>Journal of Psychiatric Research</i> , 2021, 133, 38-45.	3.1	12
143	Investigating the Relationships of P3b with Negative Symptoms and Neurocognition in Subjects with Chronic Schizophrenia. <i>Brain Sciences</i> , 2021, 11, 1632.	2.3	12
144	Rasch analysis of the PANSS negative subscale and exploration of negative symptom trajectories in first-episode schizophrenia â data from the OPTiMiSE trial. <i>Psychiatry Research</i> , 2020, 289, 112970.	3.3	11

#	ARTICLE	IF	CITATIONS
145	Exploring the role of age as a moderator of cognitive remediation for people with schizophrenia. <i>Schizophrenia Research</i> , 2021, 228, 29-35.	2.0	11
146	Investigating the Relationship between White Matter Connectivity and Motivational Circuits in Subjects with Deficit Schizophrenia: A Diffusion Tensor Imaging (DTI) Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 61.	2.4	10
147	Value of schizophrenia treatment II: Decision modelling for developing early detection and early intervention services in the Czech Republic. <i>European Psychiatry</i> , 2018, 53, 116-122.	0.2	9
148	Schizophrenia and "unmet needs": From diagnosis to care in Italy. <i>European Psychiatry</i> , 2020, 63, e26.	0.2	9
149	Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMiSE Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 444-455.	4.3	9
150	We are not ready to abandon the current schizophrenia construct, but should be prepared to do so. <i>Schizophrenia Research</i> , 2022, 242, 30-34.	2.0	9
151	Tracing Links Between Early Auditory Information Processing and Negative Symptoms in Schizophrenia: An ERP Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 790745.	2.6	9
152	Impulsiveness in Patients with Bulimia Nervosa: Electrophysiological Evidence of Reduced Inhibitory Control. <i>Neuropsychobiology</i> , 2013, 68, 116-123.	1.9	8
153	Impact of Reward and Loss Anticipation on Cognitive Control: An Event-Related Potential Study in Subjects With Schizophrenia and Healthy Controls. <i>Clinical EEG and Neuroscience</i> , 2018, 49, 46-54.	1.7	8
154	Beyond the Transnosographic Emphasis on Psychosis: Nosological Perspectives on Schizophrenia and Its Prevention. <i>Frontiers in Psychiatry</i> , 2019, 10, 666.	2.6	8
155	Mismatch Negativity and P3a Impairment through Different Phases of Schizophrenia and Their Association with Real-Life Functioning. <i>Journal of Clinical Medicine</i> , 2021, 10, 5838.	2.4	8
156	A functional comparison of patients with schizophrenia between the North and South of Europe. <i>European Psychiatry</i> , 2012, 27, 442-444.	0.2	7
157	Autism Rating Scale: A New Tool for Characterizing the Schizophrenia Phenotype. <i>Frontiers in Psychiatry</i> , 2021, 12, 622359.	2.6	7
158	Correspondence. <i>Schizophrenia Research</i> , 1995, 14, 265-266.	2.0	6
159	Familial sinistrality and handedness in patients with first episode schizophrenia: The EUFEST study. <i>Laterality</i> , 2012, 17, 217-224.	1.0	6
160	<p>The Efficacy, Feasibility And Acceptability Of A Remotely Accessible Use Of CIRCuiTS, A Computerized Cognitive Remediation Therapy Program For Schizophrenia: A Pilot Study</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 3103-3113.	2.2	6
161	"Precision psychiatry"™ needs to become part of "personalized psychiatry"™. <i>Fortschritte Der Neurologie Psychiatrie</i> , 2020, 88, 767-772.	0.5	6
162	Factors influencing lithium versus valproate prescription preference in the maintenance treatment of bipolar patients: a report from the Italian Early Career Psychiatrists (SOPSI-GG). <i>International Journal of Psychiatry in Clinical Practice</i> , 2021, 25, 82-89.	2.4	6

#	ARTICLE	IF	CITATIONS
163	Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: the OPTiMISE study. <i>Psychological Medicine</i> , 2023, 53, 3471-3479.	4.5	6
164	Factors associated with decreased platelet MAO activity in chronic schizophrenics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1987, 11, 79-86.	4.8	5
165	Motion standstill leads to activation of inferior parietal lobe. <i>Human Brain Mapping</i> , 2006, 27, 340-349.	3.6	5
166	The UN Convention on the Rights of Persons with Disabilities: great opportunities and dangerous interpretations. <i>World Psychiatry</i> , 2019, 18, 47-48.	10.4	5
167	Abnormal bodily experiences detected by Abnormal Bodily Phenomena questionnaire are more frequent and severe in schizophrenia than in bipolar disorder with psychotic features. <i>European Psychiatry</i> , 2020, 63, e49.	0.2	5
168	The Cognitive Assessment Interview (CAI): Association with neuropsychological scores and real-life functioning in a large sample of Italian subjects with schizophrenia. <i>Schizophrenia Research</i> , 2022, 241, 161-170.	2.0	5
169	Physiologic Basis of the EEG Signal. , 2011, , 7-12.		4
170	Placebo controls in clinical trials: concerns about use in relapse prevention studies in schizophrenia. <i>BMJ</i> , The, 2016, 354, i4728.	6.0	4
171	Untangling the Factors Contributing to Functional Outcome in Schizophreniaâ€”Reply. <i>JAMA Psychiatry</i> , 2018, 75, 754.	11.0	4
172	Genome-wide association study detected novel susceptibility genes for social cognition impairment in people with schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 46-54.	2.6	4
173	ITAlIAn Partnership for Psychosis Prevention (ITAPP): improving the mental health of young people. <i>European Psychiatry</i> , 2021, 64, 1-21.	0.2	4
174	Psychophysiology in psychiatry: new perspectives in the study of mental disorders. <i>World Psychiatry</i> , 2002, 1, 166-8.	10.4	4
175	Joint structural-functional magnetic resonance imaging features are associated with diagnosis and real-world functioning in patients with schizophrenia. <i>Schizophrenia Research</i> , 2022, 240, 193-203.	2.0	4
176	Negative Symptom Domains in Children and Adolescents at Ultra-High Risk for Psychosis: Association With Real-Life Functioning. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	1.7	4
177	Scalability of the Positive and Negative Syndrome Scale in firstâ€”episode schizophrenia assessed by Rasch models. <i>Acta Psychiatrica Scandinavica</i> , 2022, 146, 21-35.	4.5	4
178	Searching for bridges between psychopathology and real-world functioning in first-episode psychosis: A network analysis from the OPTiMISE trial. <i>European Psychiatry</i> , 2022, 65, .	0.2	4
179	The added value of including cognitive impairment in the diagnostic criteria for schizophrenia. <i>World Psychiatry</i> , 2008, 7, 36-37.	10.4	3
180	Current trends in diagnosis and treatment of mental disorders. <i>European Psychiatry</i> , 2018, 50, 4-6.	0.2	3

#	ARTICLE	IF	CITATIONS
181	Neuroimaging and Psychopathological Domains. , 2019, , 57-155.		3
182	Clinical applications of pharmaco-EEG in psychiatry: the prediction of response to treatment with antipsychotics. Methods and Findings in Experimental and Clinical Pharmacology, 2002, 24 Suppl C, 85-9.	0.8	3
183	Facial emotion recognition impairment is related to disorganisation in multi-episode schizophrenia. Schizophrenia Research: Cognition, 2014, 1, 122-125.	1.3	2
184	The second-generation assessment scales: Brief negative symptom scale and clinical assessment interview for negative symptoms. European Psychiatry, 2016, 33, S70-S70.	0.2	2
185	Social Cognition Individualized Activities Lab for Social Cognition Training and Narrative Enhancement in Patients With Schizophrenia: A Randomized Controlled Study to Assess Efficacy and Generalization to Real-Life Functioning (Prot. n°: NCT05130853). Frontiers in Psychiatry, 2022, 13, 833550.	2.6	2
186	Quantitative EEG reactivity to neuroleptic challenge in first-episode and chronic schizophrenics. Biological Psychiatry, 1997, 42, 64S.	1.3	1
187	Neurophysiological Research in Psychiatry. , 0, , 125-180.		1
188	DEFICIT SCHIZOPHRENIA: A VALID CATEGORICAL SUBTYPE OF SCHIZOPHRENIA?. Schizophrenia Research, 2008, 102, 45.	2.0	1
189	Effects of antipsychotics on cognitive functions: an ERP study in healthy controls. European Psychiatry, 2011, 26, 1267-1267.	0.2	1
190	EEG in Delirium and Dementia. , 2011, , 147-162.		1
191	Standard EEG in Personality and Anxiety Disorders. , 2011, , 133-146.		1
192	Social skills vs. Neurocognitive training in psychotic patients. European Psychiatry, 2011, 26, 1475-1475.	0.2	1
193	Neurophysiological correlates of negative symptom domains: an auditory oddball study in schizophrenia. European Neuropsychopharmacology, 2016, 26, S506-S507.	0.7	1
194	Relationships between neurocognition, social cognition and functional outcome in schizophrenia. European Psychiatry, 2016, 33, S67-S67.	0.2	1
195	EPA position paper: Improving the image of psychiatry and psychiatrists. European Psychiatry, 2017, 42, 24-26.	0.2	1
196	Resilience in people with schizophrenia. Results from the Italian Network for Research on Psychoses. European Journal of Public Health, 2017, 27, .	0.3	1
197	Psychiatry and psychiatrists: Fourteen core statements. European Psychiatry, 2018, 52, 136-138.	0.2	1
198	Toward Clinical Translation of Neuroimaging Research in Schizophrenia and Other Primary Psychotic Disorders. , 2019, , 327-345.		1

#	ARTICLE	IF	CITATIONS
199	Neuroimaging: Diagnostic Boundaries and Biomarkers. , 2019, , 1-56.		1
200	Neglected Vulnerabilities in Mental Health: Where Do We Need to Do More?. , 2022, , 335-369.		1
201	Determinants of Clinical Recovery in Schizophrenia. Comprehensive Approach To Psychiatry, 2022, , 23-43.	1.0	1
202	Quantitative EEG in Psychiatry: From Research to Clinical Applications. European Psychiatry, 1997, 12, 105s-105s.	0.2	0
203	EEG mapping before and after antipsychotic treatment in chronic and first-episode schizophrenics. European Psychiatry, 1998, 13, 197S-197S.	0.2	0
204	S21.02 Cognitive dysfunctions in psychotic patients: Relationship with symptoms and antipsychotic treatment. European Psychiatry, 2000, 15, 252s-252s.	0.2	0
205	Psychophysiology of Mood Disorders. , 0, , 777-790.		0
206	CS06-03 - Relationship between cognition and psychopathology. European Psychiatry, 2011, 26, 1788-1788.	0.2	0
207	Which Outcome Indices Would Clinicians Like to See in Schizophrenia Clinical Trials?. European Psychiatry, 2011, 26, 2204-2204.	0.2	0
208	Primary and enduring negative symptoms in first episode and chronic patients with schizophrenia. European Psychiatry, 2011, 26, 2068-2068.	0.2	0
209	Perception of body shape in bulimia nervosa: An ERP study. European Psychiatry, 2011, 26, 741-741.	0.2	0
210	Negative symptoms domains: pathways to functional outcome in schizophrenia. European Neuropsychopharmacology, 2016, 26, S123.	0.7	0
211	Electrophysiological mechanisms underlying ERP amplitude reduction in patients with schizophrenia: A time-frequency analysis. European Psychiatry, 2016, 33, S104-S104.	0.2	0
212	The social cognition individualized activities lab: Implementation of a new remediation intervention for social cognition. European Psychiatry, 2016, 33, S567-S567.	0.2	0
213	A comprehensive systematic screening protocol for assessment of medical comorbidities in schizophrenia. European Psychiatry, 2016, 33, S574-S574.	0.2	0
214	Relation between EEG source functional connectivity and the negative symptom severity in schizophrenia: a preliminary report from a multicentre study. European Psychiatry, 2016, 33, s246-s246.	0.2	0
215	Editorial: The EPA, Brexit and beyond. European Psychiatry, 2017, 42, 27-28.	0.2	0
216	Effects of chronic antipsychotic treatment on neurophysiological correlates of the auditory oddball task in schizophrenia: A preliminary report from a multicentre study. European Psychiatry, 2017, 41, S192-S192.	0.2	0

#	ARTICLE	IF	CITATIONS
217	Functional connectivity of the ventral tegmental area and avolition in schizophrenia: A resting state functional MRI study. <i>European Psychiatry</i> , 2017, 41, S196-S196.	0.2	0
218	Electrophysiological Correlates of Negative Symptom Domains in Schizophrenia. <i>European Psychiatry</i> , 2017, 41, S96-S97.	0.2	0
219	Disorganization in Schizophrenia: A Resting EEG Study. <i>European Psychiatry</i> , 2017, 41, S100-S100.	0.2	0
220	Future coordination and integration of the results of the EU funded projects on schizophrenia and other mental disorders. <i>European Psychiatry</i> , 2018, 50, 1-3.	0.2	0
221	White matter structural connectivity abnormalities in subjects with deficit schizophrenia: A diffusion tensor imaging study. <i>European Neuropsychopharmacology</i> , 2019, 29, S110.	0.7	0
222	Academic and social functioning in early life epochs in schizophrenia patients and first-degree unaffected relatives. <i>European Neuropsychopharmacology</i> , 2019, 29, S336.	0.7	0
223	Questionnaire on Attitude towards Research and Care (QuARC): a survey of patients with psychosis. <i>Journal of Mental Health</i> , 2020, 29, 590-596.	1.9	0
224	P.778 Electrophysiological indices and expressive deficit domain of negative symptoms in subjects with schizophrenia. <i>European Neuropsychopharmacology</i> , 2020, 40, S442.	0.7	0
225	P.307 Resting state MRI functional connectivity and negative symptoms in subjects with schizophrenia. <i>European Neuropsychopharmacology</i> , 2021, 44, S44-S45.	0.7	0
226	Selected E-INSR 2004 Conference Presentation Abstracts. <i>Journal of Neurotherapy</i> , 2005, 9, 103-108.	0.9	0
227	Haloperidol-Induced Changes of Computerized Electroencephalogram Topography in Drug-Free Schizophrenic Patients. , 1993, , 245-250.		0
228	Predicting response to antipsychotics by electrophysiological indices. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 2002, 24 Suppl D, 79.	0.8	0
229	P.0589 Resting-state functional connectivity of the ventral tegmental area and negative symptoms in subjects with schizophrenia: a resting-state functional MRI study. <i>European Neuropsychopharmacology</i> , 2021, 53, S431-S432.	0.7	0
230	P.0592 Investigating the relationships of N100-P3b with symptom dimensions and cognitive impairments in subjects with chronic schizophrenia. <i>European Neuropsychopharmacology</i> , 2021, 53, S432-S433.	0.7	0